Why Is Regeneron Pharmaceuticals (REGN) Stock Down -6% Today?
Key Takeaways
- Shares of Regeneron Pharmaceuticals (REGN) are down approximately 6% on Wednesday, trading near $688 after closing at $731.77 on April 28, in an earnings-driven selloff despite a headline beat on both EPS and revenue
- Primary catalyst: A sharp "beat and sell" market reaction driven by the continued deterioration of the core EYLEA franchise — total U.S. EYLEA HD and EYLEA net sales declined 10% year-over-year to $941 million, more than offsetting record Dupixent growth
- Secondary catalyst: Regeneron's Trump administration Most-Favored Nation (MFN) drug pricing deal — signed just six days before earnings — commits the company to significant long-term drug price reductions across Medicaid and future therapies, raising concerns about structural margin compression
- GAAP gross margin contracted due to temporary manufacturing issues disclosed in the Q1 report, adding further pressure on profitability optics
- Eylea 2mg biosimilar competition is expected to accelerate in H2 2026 as multiple additional products enter the market, a risk the market is pre-emptively pricing in
- Traders are watching the anticipated fianlimab + Libtayo melanoma Phase 3 data readout and management's H2 2026 commentary around EYLEA HD conversion pacing
Opening Summary
Regeneron Pharmaceuticals, Inc. (REGN) is a Tarrytown, New York–based biotechnology company that develops and commercializes transformative medicines, with its flagship products including the immunology blockbuster Dupixent (co-developed with Sanofi), the ophthalmology franchise EYLEA and EYLEA HD, and oncology therapy Libtayo. Shares fell approximately 6% on Wednesday, declining from a prior close of $731.77 to trade near $688, despite a Q1 2026 print that beat consensus on both adjusted EPS and revenue. The paradoxical selloff reflects a combination of EYLEA franchise deterioration, investor concern over the company's newly signed MFN drug pricing agreement with the Trump White House, and a GAAP gross margin decline tied to temporary manufacturing disruptions — all of which outweighed the headline beat in the market's eyes.
Q1 2026 Earnings: Headline Beat, Franchise Headache
Regeneron delivered Q1 2026 non-GAAP EPS of $9.47, beating the consensus estimate of $9.07 by $0.40 — a 6.56% positive surprise. Revenue reached $3.61 billion, up 19% year-over-year and ahead of the $3.55 billion consensus by approximately $53 million. Dupixent global net sales recorded by Sanofi surged 33% to $4.9 billion, sustaining its position as one of the fastest-growing blockbusters in the industry. EYLEA HD U.S. net sales grew 52% year-over-year to $468 million, validating the higher-dose reformulation strategy. However, when combining EYLEA HD with the legacy EYLEA 2mg franchise, total U.S. EYLEA net sales declined 10% year-over-year to $941 million — the most closely watched number in the quarter and the one that spooked investors most acutely. A temporary manufacturing issue also suppressed GAAP gross margins below year-ago levels, adding further optics pressure despite non-GAAP profitability.
MFN Drug Pricing Deal: Long-Term Revenue Overhang
Six days before reporting earnings, Regeneron became the 17th and final major pharmaceutical company to sign the Trump administration's Most-Favored Nation pricing agreement. Under the terms of the deal, Regeneron committed to align its current and future Medicaid drug prices with the lowest prices paid in comparable developed nations, offer its cholesterol drug Praluent on TrumpRx.gov at $225 — a 58% discount from its prior $537 price — and invest $27 billion in U.S. research, development, and manufacturing through 2029. In exchange, REGN secured a three-year exemption from pharmaceutical tariffs and immunity from future pricing mandates. While the stock initially rose 2.6% on the deal announcement, investors are now reassessing the long-term margin implications — particularly as future drug launches must be priced at most-favored-nation levels from day one, a structural constraint that affects Regeneron's highest-margin commercialization window.
Accelerating Biosimilar Pressure on EYLEA
The EYLEA franchise — historically the backbone of Regeneron's revenue — faces a worsening competitive landscape that Q1 2026 results made more concrete. EYLEA 2mg U.S. sales have been in structural decline as biosimilar competition, compounded bevacizumab substitution, and patient migration to EYLEA HD have eroded volumes. While EYLEA HD's 52% growth is encouraging, the pace of conversion has not been sufficient to fully offset the legacy product's declining base — a gap the market expects to widen materially in H2 2026 as multiple additional EYLEA biosimilar entrants are scheduled to launch. TD Cowen and other analysts have previously flagged the H2 biosimilar acceleration as the key risk that consensus estimates may only be partially pricing in, making the Q1 franchise total of $941 million a sobering preview of the trajectory ahead.
Market Context and Trading Activity
The REGN selloff was company-specific and earnings-driven, with the broader biotech and healthcare sector not registering comparable losses on Wednesday. Volume surged well above the average daily level as institutional sellers responded to the EYLEA revenue figure immediately following the pre-market earnings release. The stock entered the day already testing the lower bound of its 52-week range of $476.49–$821.11, having underperformed the Nasdaq materially since its October 2025 highs. REGN had already broken below its 50-day moving average in early April 2026 and its 10-day average had crossed bearishly below the 50-day on March 13, establishing a downtrend that Wednesday's session reinforced.
Trending AI Robots
For traders navigating volatile, earnings-driven sessions like today's REGN move, Tickeron's Trending AI Robots page provides a curated ranking of the platform's top-performing AI trading bots under current market conditions. Tickeron operates hundreds of AI bots covering thousands of tickers across biotechnology, healthcare, technology, and all major sectors — but only those demonstrating the strongest real-time performance metrics are featured in this dynamic, live-updated section. Bots vary by strategy, holding timeframe, risk tolerance, and traded symbols, spanning short-term momentum plays to multi-session swing strategies. Whether you are managing risk around post-earnings dislocations or seeking systematic approaches to capitalize on sharp directional moves, the Trending AI Robots page is a practical starting point for data-driven traders.
What Comes Next for REGN
The most closely anticipated catalyst for REGN) is the Phase 3 data readout for fianlimab plus Libtayo in first-line metastatic melanoma, expected in H1 2026, which TD Cowen and others view as a potential transformational moment for Regeneron's oncology franchise. A strong fianlimab result could establish Libtayo as a credible blockbuster competitor in a large oncology market, providing a meaningful revenue diversification catalyst beyond the Dupixent and EYLEA narratives. H2 2026 EYLEA 2mg biosimilar entry volume will be the primary ongoing financial variable — the rate of EYLEA HD conversion against accelerating legacy erosion will determine whether the retinal franchise stabilizes or declines faster than consensus. The MFN pricing framework, while temporarily resolved for REGN on tariffs, remains politically fluid — Democratic lawmakers have publicly requested detailed terms of all MFN agreements from drugmakers, and any legislative or regulatory development in this area could reprice the sector broadly. Analysts will also monitor whether the Q1 GAAP manufacturing disruption proves genuinely temporary, as any recurrence would further compress reported margins and challenge the non-GAAP narrative the company has maintained.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for REGN turns negative, indicating new downward trend
REGN saw its Momentum Indicator move below the 0 level on April 27, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned negative. In of the 89 cases, the stock moved further down in the following days. The odds of a decline are at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for REGN turned negative on April 27, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .
REGN moved below its 50-day moving average on April 24, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where REGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for REGN entered a downward trend on May 08, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where REGN's RSI Indicator exited the oversold zone, of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 55 cases where REGN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
REGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.378) is normal, around the industry mean (32.489). P/E Ratio (17.402) is within average values for comparable stocks, (51.006). Projected Growth (PEG Ratio) (1.457) is also within normal values, averaging (1.680). Dividend Yield (0.005) settles around the average of (0.033) among similar stocks. P/S Ratio (5.147) is also within normal values, averaging (337.233).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. REGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. REGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of medicines for the treatment of serious medical conditions
Industry Biotechnology
Advertisement